Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Therapy-relevant mutations of receptor tyrosine kinases in malignant thymomas and thymic carcinomas: a therapeutic perspective].

Verhandlungen der Deutschen Gesellschaft fur Pathologie - 1 Jan 2007

Ströbel P, Knop S, Einsele H, Müller-Hermelink H K, Marx A

Abstract excerpt

UNLABELLED: 50-70% of patients with malignant thymic epithelial tumors (thymomas or thymic carcinomas) cannot be cured by current treatment strategies and are therefore candidates for second line therapies. METHODS: Malignant thymomas and thymic squamous cell carcinomas (TSCC) were analyzed by genomic sequencing and functional tests using ex vivo explant cell cultures to study alterations of the receptor tyrosine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma

Share to Cetuximab

Share to Proto-Oncogene Proteins c-kit

Share to Receptor Protein-Tyrosine Kinases

Share to Thymoma

Share to Thymus Neoplasms

Source

Identifiers

PMID: 18314613

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Therapy-relevant mutations of receptor tyrosine kinases in malignant thymomas and thymic carcinomas: a therapeutic perspective].PMID 18314613Read ↗

Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic CarcinomasSemantic proximity Read ↗

Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets.Semantic proximity Read ↗

C-KIT mutation in thymic carcinomas.Semantic proximity Read ↗

Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).Semantic proximity Read ↗

Mutation analysis of the EGFR gene and its downstream signaling pathway in thymic carcinoma patients from a Chinese Han population.Semantic proximity Read ↗

Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.Semantic proximity Read ↗

Mutation Profile of Thymic Carcinoma and Thymic Neuroendocrine Tumor by Targeted Next-generation Sequencing.Semantic proximity Read ↗

Expression and mutational status of c-kit in thymic epithelial tumors.Semantic proximity Read ↗

Absence of gene mutations in KIT-positive thymic epithelial tumors.Semantic proximity Read ↗

Medical treatment involving investigational drugs and genetic profile of thymic carcinoma.Semantic proximity Read ↗

A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3Semantic proximity Read ↗

Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.